Semaglutide and tirzepatide are the two medications most people are weighing up, and they are related but not the same drug. Tirzepatide tends to produce larger average weight loss because it acts on two gut-hormone pathways instead of one, but semaglutide has the deeper track record for cardiovascular protection. For most people the decision is settled by cost, access, and how your body responds, not by which one wins on a trial leaderboard. This is a plain-language comparison of how the two work, what the head-to-head data actually shows, and the practical factors that usually decide it.
The mechanism difference
Semaglutide is a GLP-1 receptor agonist. It mimics a single gut hormone, GLP-1, that influences appetite, satiety, and blood sugar. It is the active ingredient in Wegovy (approved for weight management) and Ozempic and Rybelsus (approved for type 2 diabetes). For a detailed breakdown of how it works at a molecular level, see how semaglutide works for weight loss.
Tirzepatide is a dual agonist: it acts on the GLP-1 receptor and the GIP receptor, a second gut-hormone pathway. It is the active ingredient in Zepbound (weight management) and Mounjaro (type 2 diabetes). Adding the GIP pathway is the leading explanation for why tirzepatide has produced larger average weight loss in trials, though the full biology is still being worked out. The distinction between the two receptor systems is covered in GLP-1 vs GIP.
Semaglutide vs tirzepatide at a glance
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 agonist (single pathway) | GLP-1 + GIP agonist (dual pathway) |
| Weight brand | Wegovy | Zepbound |
| Diabetes brand | Ozempic, Rybelsus (oral) | Mounjaro |
| Dosing | Weekly injection (oral option for diabetes) | Weekly injection |
| Top-dose trial weight loss | ~14.9% (STEP 1, 68 weeks) | ~20.9% (SURMOUNT-1, 72 weeks) |
| Head-to-head result | 13.7% (SURMOUNT-5) | 20.2% (SURMOUNT-5) |
| Cardiovascular outcomes | Proven (SELECT trial) | Outcomes trial ongoing |
GLP-1 results index
Average weight loss by drug
Mean weight loss in each drug's pivotal obesity trial, over 56 to 72 weeks.
What the results look like
For years the comparison relied on separate trials. The STEP 1 trial showed a mean weight loss of about 14.9% for semaglutide 2.4 mg over 68 weeks, while the SURMOUNT-1 trial showed about 20.9% for tirzepatide 15 mg over 72 weeks. Comparing across separate trials is imperfect, because the populations and protocols differ, but the gap was large enough to be suggestive. For the full trial breakdown, see GLP-1 clinical studies explained and how much weight you can lose on semaglutide.
That changed with SURMOUNT-5, the first large head-to-head trial that put the two drugs against each other directly in adults with obesity and without diabetes. At 72 weeks, tirzepatide produced about 20.2% average weight loss versus about 13.7% for semaglutide. That is a real, measured advantage for tirzepatide rather than a cross-trial guess, and it is the single most important recent development in this comparison. Even so, "average" hides a lot of individual variation: plenty of people lose a great deal on semaglutide, and response depends on dose, consistency, diet, sleep, and biology. See our detailed tirzepatide vs semaglutide data comparison for the numbers by dose, and GLP-1 weight loss results by drug for the wider field.
Where semaglutide still has the edge: heart data
Weight loss is not the only outcome that matters. Semaglutide has the stronger cardiovascular evidence base. In the SELECT trial of more than 17,000 adults with established cardiovascular disease and obesity but without diabetes, semaglutide reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by about 20% versus placebo. That result led to an expanded label for cardiovascular risk reduction. Tirzepatide's dedicated cardiovascular outcomes trial is still running, so as of 2026 it does not yet have the same proven outcome data. If heart protection is a priority, that difference is worth raising with your prescriber. More on this in semaglutide and heart disease.
Dosing and titration
Both drugs start low and step up slowly to limit side effects, a process called titration. Semaglutide for weight management climbs through 0.25, 0.5, 1.0, 1.7, and 2.4 mg once weekly, usually over about 16 to 20 weeks. Tirzepatide climbs through 2.5, 5, 7.5, 10, 12.5, and up to 15 mg once weekly on a similar schedule. Neither is meant to be rushed: moving up before your body adjusts is the most common cause of rough side effects. See the semaglutide dosing schedule and GLP-1 dosage for weight loss for the full ladders, and the GLP-1 maintenance dose for what happens once you reach your target.
Side effects
Both drugs share the same core side-effect profile, primarily gastrointestinal: nausea, constipation or diarrhea, and reduced appetite, most prominent during titration. In SURMOUNT-5, most adverse events were mild to moderate, and gastrointestinal side effects leading to discontinuation were actually somewhat less common with tirzepatide (about 2.7%) than semaglutide (about 5.6%), though both rates were low. For the average person there is no decisive tolerability winner, because response is highly individual. Practical management is covered in managing nausea on GLP-1, the GLP-1 side-effects timeline, and what to expect in your first month.
Practical factors that often decide it
- Cost and coverage. What your insurance covers, or what is affordable through a telehealth provider, often matters more than the trial averages. See what GLP-1 medications actually cost and the GLP-1 Cost Index 2026.
- Availability. Supply of specific drugs and doses has fluctuated over time, and the best drug you cannot get consistently is not the best choice for you.
- Your health history. Existing cardiovascular disease, diabetes, tolerability on a previous drug, and other conditions all shift the calculus.
- Your prescriber's judgment. This is the factor that ties the others together, and it is why the decision belongs in a clinical conversation.
Which one should you choose?
There is no single right answer, but a few scenarios point one way or the other. If maximum average weight loss is the priority and you can access and tolerate it, the head-to-head data favors tirzepatide. If you have established cardiovascular disease, semaglutide's proven SELECT outcomes are a genuine point in its favor to raise with your prescriber. If cost or coverage is the deciding constraint, the answer is simply whichever one you can get affordably and consistently, because an effective drug you take every week beats a slightly more effective one you ration or abandon. And if you have already tried one with poor tolerability, switching to the other under guidance is reasonable. In every case the right move is to bring these trade-offs to a prescriber rather than self-select. For related decisions, see the best GLP-1 for weight loss and Wegovy vs Zepbound.
The honest takeaway
Tirzepatide's dual mechanism gives it a measured edge in average weight loss, now confirmed head-to-head in SURMOUNT-5. Semaglutide holds the stronger proven cardiovascular outcome data. Both are highly effective medications, and for most people the decision is settled by cost, access, health history, and how the body responds, not by a leaderboard. This is a conversation to have with a prescriber, not a verdict to reach from an article. For how both compare to conventional approaches, see GLP-1 vs traditional weight loss.
Frequently asked questions
Is tirzepatide just a stronger version of semaglutide?
Not exactly. It is a different molecule that acts on an additional receptor (GIP) alongside the GLP-1 receptor semaglutide targets. The added pathway is the leading explanation for its larger average weight loss, but it is a distinct drug, not a higher dose of the same one.
Which one has fewer side effects?
They share the same gastrointestinal profile, and for most people neither is clearly gentler. In the SURMOUNT-5 head-to-head, discontinuations for gastrointestinal reasons were slightly lower on tirzepatide, but both rates were low and individual response varies widely.
Can you switch from one to the other?
People do switch, usually for cost, access, tolerability, or a plateau, but it should be done under a prescriber's guidance because dosing does not transfer one-to-one between the two drugs.
This article is educational and not medical advice. Drug selection, dosing, and suitability are decisions for you and a licensed clinician.
About the author
Modern Weight Science Editorial Team
Editorial Team
Evidence-based research and educational content focused on metabolism, appetite regulation, and sustainable weight management. Our team synthesizes peer-reviewed research into clear, accessible guidance for informed health decisions.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
What is the difference between Ozempic and Wegovy?
Both contain semaglutide, but they are FDA-approved for different indications. Ozempic (up to 2mg) is approved for type 2 diabetes management and cardiovascular risk reduction. Wegovy (up to 2.4mg) is approved for chronic weight management. The distinction directly affects insurance coverage, maximum dose, and prescribing eligibility — and the two are not interchangeable through most pharmacies.
Do I need a prescription for semaglutide or tirzepatide?
Yes. Semaglutide and tirzepatide are prescription-only medications in the United States and most countries. They require evaluation and a prescription from a licensed healthcare provider. Compounded versions have been available through telehealth platforms, but these are not FDA-approved and carry different regulatory and quality considerations.
How long does it take to see results on GLP-1 medications?
Appetite changes are typically noticed in weeks 1-2. Meaningful weight loss (5-10% of body weight) generally occurs by weeks 12-20. Clinical trial results are measured at 68-72 weeks. The dose escalation schedule means the first 16-20 weeks are primarily about building tolerance, not maximum efficacy. Individual response varies significantly.
What happens when you stop taking a GLP-1 medication?
Most people regain a significant portion of lost weight within 12 months of stopping. Discontinuation studies show that the compensatory hunger and metabolic changes that GLP-1 medications suppress tend to return when the medication is withdrawn. Many clinicians now frame these as long-term treatments — similar to antihypertensives — rather than short-term interventions.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.